Can-Fite BioPharma (CANF) EBIT Growth (5y) (2019 - 2023)
Can-Fite BioPharma (CANF) EBIT Growth (5y) (2019 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 6.03% |
| Sep 30, 2023 | -37.39% |
| Jun 30, 2023 | 19.08% |
| Mar 31, 2023 | -29.96% |
| Dec 31, 2022 | 37.20% |
| Sep 30, 2022 | -32.44% |
| Jun 30, 2022 | -18.84% |
| Mar 31, 2022 | -4.37% |
| Dec 31, 2021 | 22.83% |
| Sep 30, 2021 | -28.88% |
| Jun 30, 2021 | -28.28% |
| Mar 31, 2021 | -27.07% |
| Dec 31, 2020 | -28.15% |
| Sep 30, 2020 | -30.92% |
| Jun 30, 2020 | -35.56% |
| Mar 31, 2020 | -40.85% |
| Sep 30, 2019 | -32.21% |
| Jun 30, 2019 | -37.63% |
| Mar 31, 2019 | -2.49% |